Patent Tracker
Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has collaborated on a patent tracker with Psychedelic Alpha, an independent media outlet, community and consultancy firm in the psychedelic field, and Calyx Law, a patent law boutique focusing on cannabis and psychedelics related IP. Read more about the history and process of psychedelic patents here.
1309 Patents
Psilocybin & Psilocin
Title
Methods of treating disorders with a psilocybin analog
Subject Matter
Methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
Psilocybin & Psilocin
Title
Pharmaceutical compositions of psilocin and uses thereof
Subject Matter
Pharmaceutically acceptable salts of psilocin, methods of preparation thereof and uses thereof in therapy.
Owner
Eleusis Therapeutics US, Inc.
Patent Number
WO2026058002Priority Date
09.13.2024
Status
Published
Psilocybin & Psilocin
Title
Psilocybe assay
Subject Matter
A method for assaying putative Psilocybe spores, Psilocybe tissue, or a cultured host organism that expresses Psilocybe genes.
Owner
Medicinal Genomics Corporation
Patent Number
US20260085366Priority Date
09.13.2022
Status
Published
Psilocybin & Psilocin
Title
Tryptamine prodrug
Subject Matter
Prodrugs of psychedelic tryptamine compounds, compositions comprising psychedelic tryptamine prodrug compounds, methods of making psychedelic tryptamine prodrug compounds, and methods of treating a subject with a psychedelic tryptamine prodrug compound.
Psilocybin & Psilocin
Title
Psilocin Crystalline Forms
Subject Matter
Crystalline forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) salts or cocrystals, as well as compositions, methods of preparation and methods of their use.
Psilocybin & Psilocin
Title
Combinations Comprising Psychedelics For The Treatment Of Schizophrenia And Other Neuropsychiatric And Neurologic Disorders
Subject Matter
Novel treatment approaches for treating schizophrenia patients.
Owner
Hadasit Medical Research Services and Development Ltd
Patent Number
US20260083759Priority Date
09.06.2022
Status
Published
Psilocybin & Psilocin
Title
Combination of a 5-ht2a receptor agonist and an m4 activator and use thereof
Subject Matter
Combination therapies comprising a 5-HT2A receptor agonist and an M4 activator, compositions and kits comprising the same, and methods of using the same.
Owner
Ignis Therapeutics (Suzhou) Limited
Patent Number
WO2026052097Priority Date
09.09.2024
Status
Published
MDMA
Title
Phenethylamine compounds salts, polymorphic forms and methods of use thereof
Subject Matter
Salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane
Psilocybin & Psilocin
Title
Pharmaceutically acceptable salts of psilocin and uses thereof
Subject Matter
Pharmaceutically acceptable salts of psilocin and compositions thereof.
Owner
Eleusis Therapeutics US, Inc.
Patent Number
US20260062383Priority Date
02.10.2021
Status
Published
LSD
Title
Method for improving neuroplasticity
Subject Matter
The use of a therapeutic agent in the treatment of a psychiatric condition in which depressive symptoms are prominent.
Page 1 of 131